Neupogen® (filgrastim)

BL 103353

Neupogen® (filgrastim)

BL 103353

U.S. License Holder:

Amgen

Date of License:

February-20-1991

Last Update:

December-09-2018

approved_indications FDA-Approved Indications


NEUPOGEN (filgrastim) is a leukocyte growth factor indicated to:

Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever;

Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML);

Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT);

Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis;

Reduce the incidence and duration of sequelae of severe neutropenia (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia;

Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).

approved_indications aBLA / 505(b)(2) Activity


aBLA / 505(b)(2) Approved by FDA

Zarxio®: Sandoz (March-2015); Nivestym: Pfizer (July-2018)

aBLA / 505(b)(2) Accepted by FDA

Grastofil: Apotex (February-2015) TPI G-CSF: Adello Biologics (September-2017) TX-01: Tanvex BioPharma (BLA Submission October-2018)

approved_indications Approved Foreign Follow-On Biologics / Biosimilars


Biosimilars Approved In The E.U.

Accofil (Accord Healthcare) (September-2014)
Biograstim (CT Arzneimittel) (September-2008)
Filgrastim Hexal (Hexal) (February-2009)
Grastofil (Apotex) (October-2013)
Nivestim (Hospira) (June-2010)
Ratiograstim (Ratiopharm GmbH) (September-2008)
Tevagrastim (Teva Generics) (September-2008)
Zarzio (Sandoz) (February-2009)

Biosimilars Approved In Australia

Nivestim (Hospira) (September-2010)
Tevagrastim (Aspen Pharmacare Australia) (August-2011)
Zarzio (Sandoz) (May-2013)

Biosimilars Approved In Japan

Filgrastim BS (Fuji Pharma Mochida Pharmaceutical) (November-2012)
Filgrastim BS (Sandoz) (March-2014)
Filgrastim BS (Teva Pharma Japan / Nippon Kayaku) (February-2013)

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

U.S. Patent No.
8,952,138 (Refolding Proteins Using a Chemically Controlled Redox State)

Patent Owner
Amgen Inc.; Amgen Manufacturing Ltd.

Petitioner(s)
Apotex Inc.; Apotex Corp.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Manufacturing

§ 102 Challenge Instituted
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Manufacturing

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

IPR Status
Final Written Decision (Most Challenged Claims Unpatentable, 1 Claim Not Unpatentable); Request for Rehearing Pending

U.S. Patent No.
9,856,287 (Refolding Proteins Using a Chemically Controlled Redox State)

Patent Owner
Amgen Inc.; Amgen Manufacturing Ltd.

Petitioner(s)
Adello Biologics, LLC; Amneal Pharmaceuticals, Inc.; ApoPharma USA, Inc.; Apotex Corp.; Apotex Holdings, Inc.; Apotex Inc.; Apotex Pharmaceutical Holdings Inc.; Intas Pharmaceuticals Ltd.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Manufacturing

§ 102 Challenge Instituted
Awaiting Institution Decision

§ 103 challenge
Y

Claim Types Challenged Under § 103
Manufacturing

§ 103 Challenge Instituted
Awaiting Institution Decision

Final Written Decision Issued
Y

IPR Status
Challenges also include indefiniteness, written description, and enablement. Institution Decision Pending

approved_indications U.S. Patent Litigations

PACER

Case No(s):

U.S. Patent Nos.
6,162,427 (Combination of G-CSF with a Chemotherapeutic Agent for Stem Cell Mobilization) 8,952,138 (Refolding Proteins using a Chemically Controlled Redox State)

Plaintiffs
Amgen Manufacturing, Ltd.; Amgen Inc.

Defendants
Apotex, Inc.; Apotex Corp.

Federal Circuit Appeal(s)
17-1010

Status
Consolidated with 0:15-cv-61631 (S.D. Fla.); Federal Circuit Affirmed

BPCIA
Y

U.S. Patent Nos.
9,856,287 (Refolding Proteins Using a Chemically Controlled Redox State)

Plaintiffs
Amgen Manufacturing, Ltd.; Amgen Inc.

Defendants
Apotex Corp.; Apotex Inc.

Status
Case Ongoing

BPCIA
Y

U.S. Patent Nos.
4,810,643 (Production of Pluripotent Granulocyte Colony-Stimulating Factor) 4,999,291 (Production of Pluripotent Granulocyte Colony-Stimulating Factor) 4,999,299 (Propagation Process Employing Agarose Medium) 5,621,080 (Production of Erythropoietin)

Plaintiffs
Thomas A. Simonian

Defendants
Amgen Inc.

Status
Case Terminated

BPCIA
N

U.S. Patent Nos.
9,643,997 (Capture Purification Processes for Proteins Expressed in a Non-Mammalian System)

Plaintiffs
Amgen Manufacturing, Ltd.; Amgen Inc.

Defendants
Hospira, Inc.; Pfizer Inc.

Status
Case Ongoing

BPCIA
Y

U.S. Patent Nos.
8,058,398 (Modified G-CSF Polypeptide)

Plaintiffs
Amgen Manufacturing, Ltd.; Amgen Inc.

Defendants
Teva Biopharmaceuticals USA, Inc.; Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd.

Status
Dismissed

BPCIA
N

U.S. Patent Nos.
6,180,391 (Highly Efficient Controlled Expression of Exogenous Genes in E. Coli) 7,083,948 (Polypeptide Purification Reagents and Methods for Their Use) 7,118,884 (Method for Controlling Metallophosphate Precipitation in High Cell Density Fermentations) 7,384,765 (Cell Culture Performance with Betaine) 7,427,659 (Process for Purifying Proteins in a Hydrophobic Interaction Chromatography Flow-Through Fraction) 7,662,930 (Polishing Steps Used in Multi-Step Protein Purification Processes) 7,735,525 (Thermally Insulated Apparatus for Liquid Chromatographic Analysis) 7,781,395 (Process for Purifying Proteins) 8,191,566 (Valve for Controlling the Flow of Steam and Other Fluids) 8,273,707 (Process for Purifying Proteins) 8,940,878 (Capture Purification Processes for Proteins Expressed in a Non-Mammalian System) 8,952,138 (Refolding Proteins using a Chemically Controlled Redox State) 9,418,416 (Methods and Apparati for Nondestructive Detection of Undissolved Particles in a Fluid) 9,632,095 (Device and Method for Determining Reaction Kinetics) 9,643,997 (Capture Purification Processes for Proteins Expressed in a Non-Mammalian System) 9,704.239 (Video Trigger Synchronization for Improved Particle Detection in a Vessel) 9,856,287 (Refolding Proteins Using a Chemically Controlled Redox State)

Plaintiffs
Amgen Manufacturing, Ltd.; Amgen Inc.

Defendants
Adello Biologics, LLC

Status
Case Ongoing

BPCIA
Y

U.S. Patent Nos.
6,162,427 (Combination of G-CSF with a Chemotherapeutic Agent for Stem Cell Mobilization) 8,940,878 (Capture Purification Processes for Proteins Expressed in a Non-Mammalian System)

Plaintiffs
Amgen Manufacturing, Ltd.; Amgen Inc.

Defendants
Sandoz International GmbH; Sandoz GmbH; Sandoz Inc.

Federal Circuit Appeal(s)
15-1499 18-1551

Supreme Court Appeal(s)
15-1039 (U.S.) 15-1195 (U.S.)

Status
BPCIA Interpretation: Supreme Court Vacated-in-Part, Reversed-in-Part, and Remanded; Remand to Federal Circuit: Affirmed. Infringement and Validity: Summary Judgment of Non-infringement and Invalidity Counterclaims Dismissed; Federal Circuit Appeal Pending

BPCIA
Y

related articles Related News Articles


Venable Fitzpatrick’s BiologicsHQ Monthly Injection – October 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. November 12, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – August 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. September 6, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. August 3, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – March 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. April 6, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – February 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. March 6, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – December 2017 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. January 8, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2017 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. July 26, 2017
Supreme Court Hears Oral Argument in Sandoz Inc. v. Amgen Inc. Brendan M. O'Malley, Ph.D.; Jacob T. Whitt, Ph.D. April 27, 2017
180-Day Advance Notice Of First Commercial Marketing Is Mandatory For All Biosimilar Applicants Robert S. Schwartz, Ph.D.; Corinne E. Atton; Frederick C. Millett; Erica L. Norey July 7, 2016
The Amgen v. Sandoz BPCIA Decision Stands: the Federal Circuit Denies an En Banc Rehearing Lawrence S. Perry; H. Rachael Million-Perez October 22, 2015
Amgen v. Sandoz: Divided Federal Circuit Attempts to Unravel the BPCIA Alicia A. Russo; Erin J.D. Austin September 1, 2015
Federal Circuit Halts Market Launch of the First U.S. Biosimilar Robert S. Schwartz, Ph.D.; Corinne E. Atton May 12, 2015
The FDA Approves Zarxio® Opening the Door to the U.S. Biosimilars Market Robert S. Schwartz, Ph.D.; Corinne E. Atton March 6, 2015

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

captcha